Dr. Andrew Pecora
MD, FACP, CPE
Chairman and CEO, OMI Management
Dr. Andrew Pecora is a nationally recognized expert in healthcare discovery, business and delivery, positioned at the forefront of the health-systems improvement movement. As Chairman and CEO of Outcomes Matter Innovations (OMI) Management, he serves as a national advocate for making medical practices more efficient and profitable while simultaneously improving patient care. Dr. Pecora is dedicated to pairing practices with artificial intelligence and health technologies to increase efficiencies, reduce costs, and enable physicians to better focus on healing patients.
A certified hematologist and oncologist, Dr. Pecora is one of the world’s leading experts in blood and marrow stem-cell transplantation, cellular medicine, and immunology research. He has led award-winning research funded by the National Cancer Institute and the AHEPA Research Foundation, with extensive involvement in clinical evaluation of novel agents including cancer vaccines, replication competent viruses, and targeted therapies. His laboratory and clinical work has advanced the development of engineered blood and marrow stem-cell grafts for both autologous and allogeneic transplantation, as well as cell therapy applications in regenerative medicine.
Dr. Pecora’s healthcare leadership experience includes serving as President and Physician-in-Chief of a $7 billion hospital system, where he led Value-Based Care transformation across the network. During his tenure as President of Physician Enterprise and Chief Innovation Officer at Hackensack Meridian Health, he played a pivotal role in recruiting leading oncologists, initiating innovative research and clinical trials, expanding patient care services, and introducing state-of-the-art technologies to reduce administrative burdens on healthcare professionals.
He founded and expanded the John Theurer Cancer Center (JTCC), which became one of the United States’ top 50 cancer centers and the only New Jersey institute with this prestigious designation. Dr. Pecora was instrumental in securing the center’s approval from the National Cancer Institute as a research consortium member of the NCI-approved Georgetown Lombardi Comprehensive Cancer Center Consortium in May 2019. This esteemed designation recognizes providers for their scientific leadership, community engagement, and the depth and breadth of their cancer research, representing one of just 16 NCI-designated cancer consortia nationwide.
As an innovator in healthcare information technology, Dr. Pecora founded and chairs the board of COTA, a healthcare software analytics company that enables the use of synthetic control arms for life science companies and guides value-based care delivery for payers and providers. COTA holds five patents for its core advancement, the CNA (Cota Nodal Address), which serves as the digital embodiment of a patient and their disease. In total, Dr. Pecora holds over 70 patents spanning life science and information technology domains.
His strategic leadership has been crucial in developing successful partnerships with prestigious institutions including Memorial Sloan Kettering Cancer Center and Georgetown Lombardi Cancer Center, demonstrating his ability to forge collaborations that advance cancer research and patient care on a national scale.